Skip to content

Zezhou Wang

Ontario Institute for Cancer Research/Senior Research Scientist

2025 Salary

$133,586

Total compensation $134,391, including $805 in taxable benefits.

Source: Ontario’s Public Sector Salary Disclosure — names paid $100,000 or more that year. How we build this · Report an error on this page

At a Glance
2025

Employer Rank

#51

Ontario Institute for Cancer Research

Years on List

5

2021–2025

Peak Salary

$133,586

2025

Full 2025 roster at Ontario Institute for Cancer Research →·See where $133,586 ranks →

Total Compensation History

Total compensation by yearLine chart of 5 yearly values of total compensation, from $120,942 in 2021 to $134,391 in 2025.$100K$110K$120K$130K$140K20212022202320242025
Total compensation, 2021–2025. Axis starts at $100,000, the Sunshine List disclosure threshold.

Full History
2021–2025

Take-Home Pay
(After Tax) · 2025 estimate

Zezhou Wang was paid $133,586 in 2025; after income tax, CPP and EI that is roughly $94,579, an effective income-tax rate of about 25.1%. On total compensation of $134,391, Zezhou Wang ranked #51 of 114 disclosed at Ontario Institute for Cancer Research that year, where the median salary was $128,579. It is up about 3% on the $129,231 paid in 2024. This estimate leaves out pension contributions; members of OMERS, OTPP, HOOPP or OPTrust typically take home another 7–10% less.

Estimated net pay
~$94,579
Effective income-tax rate (excl. CPP/EI)
~25.1%
CPP + EI contributions
~$5,507
All-in deduction rate (incl. CPP/EI)
~29.2%
vs. 2025 Senior Research Scientist median
−34%

Where does $133,586 rank on the Sunshine List? →

Estimate only: 2025 federal and Ontario rates, basic personal amounts, Canada employment amount and CPP/EI credits; single, employment income only, salary treated as full-year income. Ignores pension contributions (OMERS, HOOPP, OTPP, OPTrust and similar plans lower actual take-home), union dues, RRSPs and benefits.

Also at Ontario Institute for Cancer Research
2025

View all 114 employees at Ontario Institute for Cancer Research (2025) →